RXD:NYE-ProShares UltraShort Health Care (USD)

ETF | Trading--Inverse Equity |

Last Closing

USD 10.65

Change

+0.17 (+1.62)%

Market Cap

N/A

Volume

0.02M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-21 )

Largest Industry Peers for Trading--Inverse Equity

Symbol Name Price(Change) Market Cap
SH ProShares Short S&P500

+0.73 (+1.78%)

USD 0.96B
SOXS Direxion Daily Semiconductor B..

+1.58 (+9.13%)

USD 0.61B
PSQ ProShares Short QQQ

+0.77 (+2.15%)

USD 0.50B
SPXU ProShares UltraPro Short S&P50..

+1.06 (+5.26%)

USD 0.48B
SDOW ProShares UltraPro Short Dow30

+2.40 (+5.26%)

USD 0.26B
YANG Direxion Daily FTSE China Bear..

-1.76 (-4.19%)

USD 0.22B
FNGD MicroSectors FANG+ Index -3X I..

+1.03 (+8.97%)

USD 0.14B
RWM ProShares Short Russell2000

+0.56 (+3.01%)

USD 0.14B
SPDN Direxion Daily S&P 500® Bear ..

+0.19 (+1.78%)

USD 0.14B
DUST Direxion Daily Gold Miners Ind..

+2.95 (+6.73%)

USD 0.13B

ETFs Containing RXD

RLD:CA 0.00 % 0.61 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Trading--Inverse Equity) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -10.50% 31% F 9% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return -10.50% 31% F 9% A-
Trailing 12 Months  
Capital Gain 3.60% 98% N/A 47% F
Dividend Return 4.06% 79% B- 61% D-
Total Return 7.66% 98% N/A 47% F
Trailing 5 Years  
Capital Gain -67.71% 70% C- 6% D-
Dividend Return 2.76% 68% D+ 7% C-
Total Return -64.95% 69% C- 5% F
Average Annual (5 Year Horizon)  
Capital Gain 64.07% 40% F 95% A
Dividend Return 65.37% 40% F 95% A
Total Return 1.30% 60% D- 31% F
Risk Return Profile  
Volatility (Standard Deviation) 433.57% 62% D 3% F
Risk Adjusted Return 15.08% 49% F 31% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.